Baseline metabolite profiles predict the glucose-lowering efficacy of exenatide in patients with type 2 diabetes
{{output}}
Aims: Individual heterogeneity in the glucose-lowering response to glucagon-like peptide-1 receptor agonists (GLP-1RAs), including exenatide, limits efficient treatment selection for type 2 diabetes mellitus (T2DM). This study as... ...
